K. McGregor

Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia

D. Neuberg, T. Graubert, K. Ballen, 2016, Haematologica.

A phase 1 study of the antibody‐drug conjugate brentuximab vedotin with re‐induction chemotherapy in patients with CD30‐expressing relapsed/refractory acute myeloid leukemia

D. Neuberg, T. Graubert, K. Ballen, 2019, Cancer.

Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia.

P. D. Dal Cin, A. Fathi, Yi-Bin Chen, 2020, Blood advances.

Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial.

Traci M. Blonquist, D. Neuberg, T. Graubert, 2019, The Lancet. Haematology.

Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutation

Traci M. Blonquist, D. Neuberg, K. Ballen, 2018, Cancer.

Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population‐based study

D. Neuberg, K. Ballen, A. Fathi, 2017, Cancer.